Gut
Overview
Gut is a renowned peer-reviewed journal dedicated to advancing the understanding of gastrointestinal diseases. It publishes cutting-edge research on various aspects of gastroenterology, including clinical studies, molecular biology, and immunology. With a focus on high-quality articles, Gut serves as a valuable resource for healthcare professionals and researchers seeking to enhance their knowledge of digestive disorders and improve patient care.
Details
Details
Abbr.
Gut
Start
1960
End
Continuing
Frequency
Sixteen no. a year, 2009-
p-ISSN
0017-5749
e-ISSN
1468-3288
Country
United Kingdom
Language
English
Specialty
Gastroenterology
Metrics
Metrics
h-index / Ranks: 126
348
SJR / Ranks: 109
8052
CiteScore / Ranks: 61
47.40
JIF / Ranks: 117
24.5
Recent Articles
1.
Kou F, Li X, Feng Z, Hua J, Wu X, Gao H, et al.
Gut
. 2025 Mar;
PMID: 40074327
Background: GPR171 suppresses T cell immune responses involved in antitumour immunity, while its role in inflammatory bowel disease (IBD) pathogenesis remains unclear. Objective: We aimed to investigate the role of...
2.
Andreyev J, Adams R, Bornschein J, Chapman M, Chuter D, Darnborough S, et al.
Gut
. 2025 Mar;
PMID: 40068855
Background: Survival rates after a diagnosis of cancer are improving. Poorly managed gastrointestinal (GI) side effects can interfere with delivery of curative cancer treatment. Long-term physical side effects of cancer...
3.
Wang C, Felli E, Fallowfield J, Dietrich C, Rockey D, Hennig J, et al.
Gut
. 2025 Mar;
PMID: 40044498
Chronic liver disease is a cluster of disorders associated with complex haemodynamic alterations, which is characterised by structural and functional disruptions of the intrahepatic and extrahepatic vasculature. 'Vasomics' is an...
4.
Gauci J, Mandarino F, Kerrison C, Whitfield A, OSullivan T, Gupta S, et al.
Gut
. 2025 Mar;
PMID: 40044497
Background: Lesion size is an independent risk factor for recurrence following endoscopic mucosal resection of large (≥20 mm) non-pedunculated colorectal polyps. Post-resection margin thermal ablation (MTA) reduces the risk of...
5.
Zhu C, Boucheron N, Al-Rubaye O, Chung B, Thorbjornsen L, Kocher T, et al.
Gut
. 2025 Mar;
PMID: 40032499
Background: 24-Nor-ursodeoxycholic acid (NorUDCA) is a novel therapeutic bile acid for treating immune-mediated cholestatic liver diseases, such as primary sclerosing cholangitis (PSC). Objective: Since PSC strongly associates with T helper-type-like...
6.
Li G, He J, Shi J, Li X, Liu L, Ge X, et al.
Gut
. 2025 Mar;
PMID: 40032498
Background: To treat liver failure, three-dimensional (3D) bioprinting is a promising technology used to construct hepatic tissue models. However, current research on bioprinting of hepatic tissue models primarily relies on...
7.
8.
Celsa C, Pennisi G, Tulone A, Ciancimino G, Vaccaro M, Infantino G, et al.
Gut
. 2025 Feb;
PMID: 40015951
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promising effects on liver histology in phase 2 trials enrolling patients with metabolic dysfunction-associated steatotic liver disease. However, the impact of GLP-1RAs...
9.
Xie W, Yin Q, Fang H, Yang K, Xue H, Zheng H, et al.
Gut
. 2025 Feb;
PMID: 40015950
No abstract available.
10.
Hu M, Xu Y, Wang Y, Huang Z, Wang L, Zeng F, et al.
Gut
. 2025 Feb;
PMID: 40015949
Background: Gut microbial metabolites are recognised as critical effector molecules that influence the development of colorectal cancer (CRC). Peptidoglycan fragments (PGFs) produced by microbiota play a crucial role in maintaining...